Precision radiation tested to fight back against returning blood cancer
NCT ID NCT01794572
Summary
This study tested a new, more precise form of radiation aimed only at the bone marrow, combined with high-dose chemotherapy and a patient's own stem cells, for people whose multiple myeloma has returned. The goal was to see if this intensive treatment approach was safe and to find the best radiation dose to control the cancer. It was designed for patients under 65 whose cancer was in remission after their relapse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Claude Huriez, service d'hématologie
Lille, 59037, France
-
CHU Haut-Leveque, service d'Hématologie
Bordeaux, 33604, France
-
CHU Hautepierre, service d'hématologie
Strasbourg, 67098, France
-
CHU Hotel-Dieu, service d'hématologie
Nantes, 44093, France
-
CLCC Bergonie, service de radiotherapie
Bordeaux, 33076, France
-
CLCC ICO, service de radiothérapie
Saint-Herblain, 44805, France
-
CLCC Oscar Lambret, service de radiothérapie
Lille, 59020, France
-
CLCC Paul Strauss, service de radiothérapie
Strasbourg, 67091, France
Conditions
Explore the condition pages connected to this study.